Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation.

Axonal degeneration contributes to clinical disability in the acquired demyelinating disease multiple sclerosis. Axonal degeneration occurs during acute attacks, associated with inflammation, and during the chronic progressive phase of the disease in which inflammation is not prominent. To explore the importance of interactions between oligodendrocytes and axons in the CNS, we analysed the brains of rodents and humans with a null mutation in the gene encoding the major CNS myelin protein, proteolipid protein (PLP1, previously PLP). Histological analyses of the CNS of Plp1 null mice and of autopsy material from patients with null PLP1 mutations were performed to evaluate axonal and myelin integrity. In vivo proton magnetic resonance spectroscopy (MRS) of PLP1 null patients was conducted to measure levels of N-acetyl aspartate (NAA), a marker of axonal integrity. Length-dependent axonal degeneration without demyelination was identified in the CNS of Plp1 null mice. Proton MRS of PLP1-deficient patients showed reduced NAA levels, consistent with axonal loss. Analysis of patients' brain tissue also demonstrated a length-dependent pattern of axonal loss without significant demyelination. Therefore, axonal degeneration occurs in humans as well as mice lacking the major myelin protein PLP1. This degeneration is length-dependent, similar to that found in the PNS of patients with the inherited demyelinating neuropathy, CMT1A, but is not associated with significant demyelination. Disruption of PLP1-mediated axonal--glial interactions thus probably causes this axonal degeneration. A similar mechanism may be responsible for axonal degeneration and clinical disability that occur in patients with multiple sclerosis.

[1]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[2]  J. Masdeu,et al.  Localization in Clinical Neurology , 1985 .

[3]  F. Muntoni,et al.  Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene , 1998, Neurology.

[4]  G. Kraft,et al.  Proteolipid Protein Is Necessary in Peripheral as Well as Central Myelin , 1997, Neuron.

[5]  S. Malcolm,et al.  The proteolipid protein gene and myelin disorders in man and animal models. , 2000, Human molecular genetics.

[6]  R. Schiffmann,et al.  Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations , 2001, Neurology.

[7]  Virginia M. Y. Lee,et al.  Formation of Compact Myelin Is Required for Maturation of the Axonal Cytoskeleton , 1999, The Journal of Neuroscience.

[8]  J. Frederiksen,et al.  Acute optic neuritis: Myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system , 1995, Annals of neurology.

[9]  Manabu Onuki,et al.  Axonal degeneration is an early pathological feature in autoimmune‐mediated demyelination in mice , 2001, Microscopy research and technique.

[10]  M. Klugmann,et al.  Late‐onset neurodegeneration in mice with increased dosage of the proteolipid protein gene , 1998, The Journal of comparative neurology.

[11]  P M Matthews,et al.  Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient , 1997, Neurology.

[12]  M. Shy,et al.  Neurological Dysfunction And Axonal Degeneration In Charcot‐Marie‐Tooth Disease Type 1A , 2001 .

[13]  H. McFarland,et al.  Identification of a second T cell epitore of human proteolipid protein (residues 89–106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients , 1994, Journal of Neuroimmunology.

[14]  F. Seitelberger Neuropathology and Genetics of Pelizaeus‐Merzbacher Disease , 1995, Brain pathology.

[15]  C. Bolton,et al.  Clinical and pathological observations in men lacking the gap junction protein connexin 32 , 2000, Muscle & nerve. Supplement.

[16]  Jens Frahm,et al.  Regional Age Dependence of Human Brain Metabolites from Infancy to Adulthood as Detected by Quantitative Localized Proton MRS , 1999, Pediatric Research.

[17]  T. Olsson,et al.  Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls , 1991, European journal of immunology.

[18]  V. Timmerman,et al.  Charcot‐Marie‐Tooth Neuropathy Type 2 and P0 Point Mutations: Two Novel Amino Acid Substitutions (Asp61Gly; Tyr119Cys) and a Possible “Hotspot” on Thr124Met , 2000, Brain pathology.

[19]  T. Tabira,et al.  DM-20, a proteolipid apoprotein, is an encephalitogen of acute and relapsing autoimmune encephalomyelitis in mice. , 1986, Journal of immunology.

[20]  L. Weiner,et al.  Isolation and characterization of autoreactive moteolioid protein‐peptide specific T‐cell clones from multiple sclerosis patients , 1995, Neurology.

[21]  L. Weiner,et al.  Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. , 1995, Neurology.

[22]  J. Duyn,et al.  Quantitative proton MR spectroscopic imaging of the human brain , 1996, Magnetic resonance in medicine.

[23]  W. Hickey,et al.  Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides , 1991, Journal of Neuroimmunology.

[24]  W. Brown,et al.  Genotype/Phenotype Correlations in X‐Linked Dominant Charcot‐Marie‐Tooth Disease , 1999, Annals of the New York Academy of Sciences.

[25]  M. Klugmann,et al.  Myelin proteolipid proteins promote the interaction of oligodendrocytes and axons , 2001, Journal of neuroscience research.

[26]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[27]  K. Nave,et al.  Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. , 1998, Science.

[28]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[29]  J H Duyn,et al.  Multisection proton MR spectroscopic imaging of the brain. , 1993, Radiology.

[30]  L. Averbuch‐Heller Localization in Clinical Neurology, 3rd Ed. , 1997, Neurology.

[31]  P. Latour,et al.  Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene , 1999, Journal of neurology, neurosurgery, and psychiatry.

[32]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[33]  K. Jellinger,et al.  Pelizaeus-Merzbacher disease , 1969, Acta Neuropathologica.

[34]  K. Jellinger,et al.  Pelizacus-Merzbacher disease. Transitional form between classical and co-natal (Seitelberger) type. , 1969, Acta neuropathologica.

[35]  H. McFarland,et al.  Identification of a novel T cell epitope of human proteolipid protein (residues 40–60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients , 1993, Journal of Neuroimmunology.

[36]  K. Nave,et al.  Assembly of CNS Myelin in the Absence of Proteolipid Protein , 1997, Neuron.

[37]  P M Matthews,et al.  Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. , 2000, Archives of neurology.

[38]  J. Frahm,et al.  Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS , 1998, Magnetic resonance in medicine.

[39]  E. Jacobs,et al.  Identification of a New Exon in the Myelin Proteolipid Protein Gene Encoding Novel Protein Isoforms That Are Restricted to the Somata of Oligodendrocytes and Neurons , 1999, The Journal of Neuroscience.

[40]  W. Brown,et al.  Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease. , 1999, Annals of the New York Academy of Sciences.

[41]  Scott T. Brady,et al.  Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells , 1992, Cell.

[42]  R E Lenkinski,et al.  MR proton spectroscopy in multiple sclerosis. , 1992, AJNR. American journal of neuroradiology.

[43]  W. Brown,et al.  X-linked dominant hereditary motor and sensory neuropathy. , 1990, Brain : a journal of neurology.

[44]  H. Clark,et al.  Myelin proteolipid protein induces demyelinating disease in mice , 1987, Journal of the Neurological Sciences.

[45]  C. van Broeckhoven,et al.  The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. , 1999, Brain : a journal of neurology.

[46]  L. Lapham,et al.  A NEW PARAFFIN METHOD FOR THE COMBINED STAINING OF MYELIN AND GLIAL FIBERS. , 1964, Journal of neuropathology and experimental neurology.

[47]  M. Koltzenburg,et al.  Loss of Distal Axons and Sensory Merkel Cells and Features Indicative of Muscle Denervation in Hindlimbs of P0-Deficient Mice , 1999, The Journal of Neuroscience.